amsterdam

BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 - The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study.

IRVINE, California, and AMSTERDAM, December 22, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today that together with several groups of scientific collaborators it has identified a major role for TSPYL5, one of its MammaPrint breast cancer prognosis genes, in the genesis of breast cancer.

IRVINE, California, and AMSTERDAM, August 5, 2010 - Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA.

IRVINE, California, and AMSTERDAM, July 15, 2010 - Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr.

HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 - Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test.